Cargando…

Short-term outcomes in patients with center-involving diabetic macular edema after a single dose of intravitreal bevacizumab

BACKGROUND: A significant portion of diabetic macular edema (DME) is refractory to anti-vascular endothelial growth factor (anti-VEGF) agents. This study investigates morphological and functional outcomes to a single intravitreal bevacizumab (IVB) injection in patients with center-involving DME (ciD...

Descripción completa

Detalles Bibliográficos
Autores principales: Turski, Christopher A., Jacobs, Mitchell A., Abou-Jaoude, Michelle M., Fowler, Nicholas H., Harpole, Ryan, Altman, Emily, Chadwell, John B., Kindl, Gabriel, James, Hayley R., Reddy, Shivani V., Maldonado, Ramiro S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9673338/
https://www.ncbi.nlm.nih.gov/pubmed/36397121
http://dx.doi.org/10.1186/s40942-022-00430-z
_version_ 1784832922836008960
author Turski, Christopher A.
Jacobs, Mitchell A.
Abou-Jaoude, Michelle M.
Fowler, Nicholas H.
Harpole, Ryan
Altman, Emily
Chadwell, John B.
Kindl, Gabriel
James, Hayley R.
Reddy, Shivani V.
Maldonado, Ramiro S.
author_facet Turski, Christopher A.
Jacobs, Mitchell A.
Abou-Jaoude, Michelle M.
Fowler, Nicholas H.
Harpole, Ryan
Altman, Emily
Chadwell, John B.
Kindl, Gabriel
James, Hayley R.
Reddy, Shivani V.
Maldonado, Ramiro S.
author_sort Turski, Christopher A.
collection PubMed
description BACKGROUND: A significant portion of diabetic macular edema (DME) is refractory to anti-vascular endothelial growth factor (anti-VEGF) agents. This study investigates morphological and functional outcomes to a single intravitreal bevacizumab (IVB) injection in patients with center-involving DME (ciDME) at 4–6 weeks and compares treatment responders and non-responders based on spectral domain optical coherence tomography (SD-OCT) features. METHODS: IRB approved observational, retrospective chart review of patients with ciDME, identified by ICD-10 code, who received IVB and underwent baseline and 4–6 weeks follow-up SD-OCT imaging between January 1, 2016 and January 19, 2021. Patients who had received previous treatment with anti-VEGF or intraocular steroids within 1 year were excluded. Variables included best-corrected visual acuity (BCVA), central subfield thickness (CST) and total macular volume (TMV). Eyes were classified as responders if CST reduction was greater than 10%. OCT scans were graded qualitatively by two masked graders using Imagivault software. Paired Student’s t-tests, Wilcoxon signed rank tests and Chi-Square tests were used for analysis. RESULTS: A total of 334 prospective subjects were identified, and after applying exclusion criteria 52 eyes from 46 patients (mean age 64.22 ± 8.12 years, 58.7% male) were included. Mean BCVA did not significantly change with treatment, 63.9 ETDRS letters (~ 20/50) at baseline and 65.9 ETDRS letters (~ 20/50) post-treatment (p = 0.07). Mean CST decreased from 466 ± 123 μm at baseline to 402 ± 86 μm post-treatment (p < 0.001). 22 (42.3%) of eyes were categorized as responders and 30 (57.7%) as non-responders. Average change in CST from baseline in responders was -164 μm (p < 0.001) and + 9 μm in non-responders (p = 0.47). Vitreomacular adhesion (VMA) was more prevalent in non-responders (28.7% vs. 4.8%, p = 0.03). In addition, cyst location in the inner nuclear layer (INL) was present more frequently in responders (95.5% vs. 73.3%, p = 0.037) as was subretinal fluid (45.5% vs. 13.3%, p = 0.01). CONCLUSION: The short-term response to a single IVB was sub-optimal with structural but no functional improvements. Greater baseline CST, presence of INL cysts and subretinal fluid may represent factors indicative of a better treatment response.
format Online
Article
Text
id pubmed-9673338
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-96733382022-11-19 Short-term outcomes in patients with center-involving diabetic macular edema after a single dose of intravitreal bevacizumab Turski, Christopher A. Jacobs, Mitchell A. Abou-Jaoude, Michelle M. Fowler, Nicholas H. Harpole, Ryan Altman, Emily Chadwell, John B. Kindl, Gabriel James, Hayley R. Reddy, Shivani V. Maldonado, Ramiro S. Int J Retina Vitreous Original Article BACKGROUND: A significant portion of diabetic macular edema (DME) is refractory to anti-vascular endothelial growth factor (anti-VEGF) agents. This study investigates morphological and functional outcomes to a single intravitreal bevacizumab (IVB) injection in patients with center-involving DME (ciDME) at 4–6 weeks and compares treatment responders and non-responders based on spectral domain optical coherence tomography (SD-OCT) features. METHODS: IRB approved observational, retrospective chart review of patients with ciDME, identified by ICD-10 code, who received IVB and underwent baseline and 4–6 weeks follow-up SD-OCT imaging between January 1, 2016 and January 19, 2021. Patients who had received previous treatment with anti-VEGF or intraocular steroids within 1 year were excluded. Variables included best-corrected visual acuity (BCVA), central subfield thickness (CST) and total macular volume (TMV). Eyes were classified as responders if CST reduction was greater than 10%. OCT scans were graded qualitatively by two masked graders using Imagivault software. Paired Student’s t-tests, Wilcoxon signed rank tests and Chi-Square tests were used for analysis. RESULTS: A total of 334 prospective subjects were identified, and after applying exclusion criteria 52 eyes from 46 patients (mean age 64.22 ± 8.12 years, 58.7% male) were included. Mean BCVA did not significantly change with treatment, 63.9 ETDRS letters (~ 20/50) at baseline and 65.9 ETDRS letters (~ 20/50) post-treatment (p = 0.07). Mean CST decreased from 466 ± 123 μm at baseline to 402 ± 86 μm post-treatment (p < 0.001). 22 (42.3%) of eyes were categorized as responders and 30 (57.7%) as non-responders. Average change in CST from baseline in responders was -164 μm (p < 0.001) and + 9 μm in non-responders (p = 0.47). Vitreomacular adhesion (VMA) was more prevalent in non-responders (28.7% vs. 4.8%, p = 0.03). In addition, cyst location in the inner nuclear layer (INL) was present more frequently in responders (95.5% vs. 73.3%, p = 0.037) as was subretinal fluid (45.5% vs. 13.3%, p = 0.01). CONCLUSION: The short-term response to a single IVB was sub-optimal with structural but no functional improvements. Greater baseline CST, presence of INL cysts and subretinal fluid may represent factors indicative of a better treatment response. BioMed Central 2022-11-17 /pmc/articles/PMC9673338/ /pubmed/36397121 http://dx.doi.org/10.1186/s40942-022-00430-z Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Original Article
Turski, Christopher A.
Jacobs, Mitchell A.
Abou-Jaoude, Michelle M.
Fowler, Nicholas H.
Harpole, Ryan
Altman, Emily
Chadwell, John B.
Kindl, Gabriel
James, Hayley R.
Reddy, Shivani V.
Maldonado, Ramiro S.
Short-term outcomes in patients with center-involving diabetic macular edema after a single dose of intravitreal bevacizumab
title Short-term outcomes in patients with center-involving diabetic macular edema after a single dose of intravitreal bevacizumab
title_full Short-term outcomes in patients with center-involving diabetic macular edema after a single dose of intravitreal bevacizumab
title_fullStr Short-term outcomes in patients with center-involving diabetic macular edema after a single dose of intravitreal bevacizumab
title_full_unstemmed Short-term outcomes in patients with center-involving diabetic macular edema after a single dose of intravitreal bevacizumab
title_short Short-term outcomes in patients with center-involving diabetic macular edema after a single dose of intravitreal bevacizumab
title_sort short-term outcomes in patients with center-involving diabetic macular edema after a single dose of intravitreal bevacizumab
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9673338/
https://www.ncbi.nlm.nih.gov/pubmed/36397121
http://dx.doi.org/10.1186/s40942-022-00430-z
work_keys_str_mv AT turskichristophera shorttermoutcomesinpatientswithcenterinvolvingdiabeticmacularedemaafterasingledoseofintravitrealbevacizumab
AT jacobsmitchella shorttermoutcomesinpatientswithcenterinvolvingdiabeticmacularedemaafterasingledoseofintravitrealbevacizumab
AT aboujaoudemichellem shorttermoutcomesinpatientswithcenterinvolvingdiabeticmacularedemaafterasingledoseofintravitrealbevacizumab
AT fowlernicholash shorttermoutcomesinpatientswithcenterinvolvingdiabeticmacularedemaafterasingledoseofintravitrealbevacizumab
AT harpoleryan shorttermoutcomesinpatientswithcenterinvolvingdiabeticmacularedemaafterasingledoseofintravitrealbevacizumab
AT altmanemily shorttermoutcomesinpatientswithcenterinvolvingdiabeticmacularedemaafterasingledoseofintravitrealbevacizumab
AT chadwelljohnb shorttermoutcomesinpatientswithcenterinvolvingdiabeticmacularedemaafterasingledoseofintravitrealbevacizumab
AT kindlgabriel shorttermoutcomesinpatientswithcenterinvolvingdiabeticmacularedemaafterasingledoseofintravitrealbevacizumab
AT jameshayleyr shorttermoutcomesinpatientswithcenterinvolvingdiabeticmacularedemaafterasingledoseofintravitrealbevacizumab
AT reddyshivaniv shorttermoutcomesinpatientswithcenterinvolvingdiabeticmacularedemaafterasingledoseofintravitrealbevacizumab
AT maldonadoramiros shorttermoutcomesinpatientswithcenterinvolvingdiabeticmacularedemaafterasingledoseofintravitrealbevacizumab